Patents
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
06/2005
06/30/2005CA2547060A1 Pharmaceutical preparation comprising an antibody against the egf receptor
06/30/2005CA2545760A1 Use of ondansetron for the treatment of inflammation, and pharmaceutical compositions thereof
06/29/2005EP1548029A2 Peptid- and peptide mimetic derivatives having integrin inhibitor properties III
06/29/2005EP1547626A2 Carrier with solid fibrinogen and solid thrombin
06/29/2005EP1547607A1 Bacterial cell wall skeleton component preparation
06/29/2005EP1547604A1 Medicinal composition for periodontal pocket administration containing bisphosphonic acid derivative or its salt as the active ingredient
06/29/2005EP1547600A1 Female hormone-containing patch
06/29/2005EP1547599A1 Transparent eye drops containing latanoprost
06/29/2005EP1547595A1 Patch for transdermal administration
06/29/2005EP1547589A1 Pasting agent
06/29/2005EP1547584A1 Particulate product comprising pantethine
06/29/2005EP1547583A2 Capsule comprising low-substituted cellulose ether
06/29/2005EP1547579A1 Adhesive gel composition for iontophoresis preparation and process for producing the same
06/29/2005EP1547170A1 Method for manufacture of films containing insoluble solids embedded in cellulose-based films
06/29/2005EP1546361A1 Auto-stimulating cells and method for making and using the same
06/29/2005EP1546235A2 Water-soluble polymer alkanals
06/29/2005EP1546216A2 Methods of drug delivery using sulphated chitinous polymers
06/29/2005EP1546203A2 Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
06/29/2005EP1546193A1 Pegylated t1249 polypeptide
06/29/2005EP1546173A2 Methods of down regulating target gene expression in vivo by introduction of interfering rna
06/29/2005EP1545994A1 Injectable pharmaceutical suspension in a two-chamber vial
06/29/2005EP1545756A2 Method for incorporating anionic molecules into a substrate for increasing dispersibility of anionic molecules
06/29/2005EP1545735A2 Method for incorporating cationic molecules into a substrate for increasing dispersibility of cationic molecules
06/29/2005EP1545705A2 Flexible and/or elastic brachytherapy seed or strand
06/29/2005EP1545626A1 Materials and methods relating to polyions and substance delivery
06/29/2005EP1545623A1 Conjugates of insulin-like growth factor binding protein-4 and poly (ethylene glycol)
06/29/2005EP1545622A1 Mucoadhesive composition and formulation for solubilization of insoluble drugs and preparation method thereof
06/29/2005EP1545621A1 Carrier
06/29/2005EP1545620A1 Pharmaceutical compositions comprising cyclosporin for oral administration
06/29/2005EP1545619A2 Solution for ungual application
06/29/2005EP1545613A2 Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
06/29/2005EP1545600A2 Protein and peptide expression for passive immunity
06/29/2005EP1545597A2 Immunostimulatory compositions and methods of stimulating an immune response
06/29/2005EP1545596A2 Use of histamine h4 receptor modulators for the treatment of allergy and asthma
06/29/2005EP1545595A2 Modified transferrin fusion proteins comprising duplicate transferrin amino or carboxy terminal domains
06/29/2005EP1545576A2 Methods of using non-human animal apoliprotein a-i protein
06/29/2005EP1545572A2 Conjugates activated by cell surface proteases and therapeutic uses thereof
06/29/2005EP1545563A1 Composition and method for use in intestinal cleansing procedures
06/29/2005EP1545553A1 Use of alkyl phosphocholines in combination with antitumor medicaments
06/29/2005EP1545550A2 Isosorbide mononitrate compositions and methods of their use
06/29/2005EP1545548A1 The use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis
06/29/2005EP1545516A2 Topical formulation comprising at least 5% of metronidazole in white petrolatum and its use in the anal and rectal region
06/29/2005EP1545500A1 Paclitaxel composition for the intravesical treatment of bladder tumor and preparation method thereof
06/29/2005EP1545499A1 Composition for solubilization of paclitaxel and preparation method thereof
06/29/2005EP1545465A1 Delayed release anti-viral product, use and formulation thereof
06/29/2005EP1545463A1 Crystalline drug particles prepared using a controlled precipitation (recrystallization) process
06/29/2005EP1545462A2 Dendrimers as molecular translocators
06/29/2005EP1545457A2 Cell transport compositions and uses thereof
06/29/2005EP1545453A1 Methods and reagents for treating infections of clostridium difficile and diseases associated therewith
06/29/2005EP1545447A2 Breath freshening and oral cleansing product using salicylaldehyde
06/29/2005EP1545429A2 Methods and compositions for treatment of dermal conditions
06/29/2005EP1545206A2 Compositions and products containing enantiomeric equol, and methods for their making
06/29/2005EP1408943B1 Pharmaceutical formulation containing an ltb4 antagonist and a wetting agent
06/29/2005EP1339408B1 Liquid drug formulations having improved oral tolerability
06/29/2005EP1276505A4 Mixtures of triblock polyesterpolyethylene glycol copolymers
06/29/2005EP1272507B1 Integrin binding peptide derivatives
06/29/2005EP1225951B1 A dual adhesive transdermal drug delivery system
06/29/2005EP1165077B1 Viral treatment
06/29/2005EP1146861B1 Hydrogel particle formulations
06/29/2005EP1140114B1 Pharmaceutical formulations
06/29/2005EP1121425B1 Stabilized bioactive peptides and methods of identification, synthesis and use
06/29/2005EP0909562B1 Injections containing lipid a analogues and process for the preparation thereof
06/29/2005EP0862456B1 Hyaluronidase compositions for treating intravitreal hemorrhagic blood
06/29/2005EP0671906B1 Bioadhesive microspheres and their use as drug delivery and imaging systems
06/29/2005CN1633440A Derivatives of branched-chain lipophilic molecules and uses thereof
06/29/2005CN1633437A Metal substituted non centrosimmetrical phthalocyanine analogues, their preparation and use in photodynamic therapy and in vivo diagnostic
06/29/2005CN1633407A Carboxylic acid compounds for use as surfactants
06/29/2005CN1633309A Method of radio-labelling biomolecules
06/29/2005CN1633308A Treatment of ophthalmic disorders using urea and urea derivatives
06/29/2005CN1633307A Oral solid solution formulation of a poorly water-soluble active substance
06/29/2005CN1633306A Viral inhibition by n-docosanol
06/29/2005CN1633305A Pharmaceutical compositions based on anticholinergics and additional active ingredients
06/29/2005CN1633300A Percutaneous preparations
06/29/2005CN1633285A 组合物 The composition
06/29/2005CN1633281A Intraorally disintegrating valdecoxib compositions
06/29/2005CN1633280A Topical composition containing at least one vitamin D or one vitamin D analogue and at least one corticosteroid
06/29/2005CN1633245A Water-dispersible coenzyme q10 dry powders
06/29/2005CN1632116A Enhancement of virus-mediated DNA transfer
06/29/2005CN1631937A Polypeptide grafted copolymer for preparation of nano drug-carrying micell
06/29/2005CN1631357A Reversal temperature sensitive injection type in situ forming and embedding formulation
06/29/2005CN1208381C Rapidly decomposing chitosan-based pellets
06/29/2005CN1208091C Virus deactivating method with immobilized solvent or immobilized solvent-detergent
06/29/2005CN1208090C Pregelatinized starch in controlled release formulation
06/29/2005CN1208065C Synergistic inhibition of viral replication long-chain hydrocarbons and nucleoside analogs
06/29/2005CN1208058C Oxazolidinone tablet formulation
06/29/2005CN1208054C Sustained releasing huperzine preparation
06/29/2005CN1208050C Plaster containing an active agent
06/29/2005CN1208047C Self-emulsifying formulation for lipophilic compounds
06/29/2005CN1208041C O/W/O type polyphase emulsion
06/28/2005US6911535 Biomolecule/polymer conjugates
06/28/2005US6911496 Composition for administration of a biologically active compound
06/28/2005US6911479 Side effect reduction; purity; removal of stereoisomers
06/28/2005US6911455 Use of pharmaceutically active agents known to cause histamine release when intravenously administered to an animal
06/28/2005US6911441 Prolonged release pharmaceutical composition
06/28/2005US6911436 Pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same
06/28/2005US6911427 No-modified hemoglobins and uses therefore
06/28/2005US6911425 Integrin binding motif containing peptides and methods of treating skeletal diseases
06/28/2005US6911227 Gels for encapsulation of biological materials
06/28/2005US6911218 Microparticles of a free carboxyl group polymer and a free amino group drug, dissolving in acetone, acetonitrile, ethyl acetate, tetrahydrofuran, or glyme and atomizing in a nozzle to an ethanol or isopropanol dispersion
06/28/2005US6911213 Pernasally absorbable insulin preparations